Transdermal Patch Growth Relying on Improved Designs, Enhanced Manufacturing Methods - Future Demand Linked to Patient Acceptance
Main Category: Pharma Industry / Biotech IndustryAlso Included In: Dermatology
Article Date: 06 Sep 2007 - 1:00 PDT
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
As competition among prescription drugs escalates, driven in part by direct-to-consumer advertising, the role of combination products in meeting market expectations and extending patent life is increasing. Drug products for which alternative delivery methods exist are highly susceptible to patient and caregiver perceptions. Since a significant interest in transdermal drug delivery patches is based on the perception that patches are more convenient, ease-of-use in accessing and applying drug patches is a critical demand factor.
Shire's recent partial withdrawal of some Daytrana ADHD patches because of feedback from patients and caregivers who have experienced difficulty removing the release liner from patches underscores the need for players in this segment to not only measure and analyze user issues during the patch product clinical trial process, but to continue to monitor patient acceptance after market launch. In response to the Daytrana feedback, the company is using an enhanced process to offer patients and caregivers improved ease of use when peeling the release liner off the patches.
The market leaders in patch design and manufacturing, a select group that includes 3M and Noven, are addressing patient concerns by developing patches that are smaller and more esthetic. Extending patch technology to new drug classes and therapeutic targets will require further enhancements to address dosing issues and patient-to-patient variability.
More information is available at http://www.greystoneassociates.org/Skin_Patches.htm.
About Greystone
Greystone Associates is a medical and healthcare technology consulting firm providing services in strategic planning, venture development, product commercialization, and technology and market assessment.
http://www.greystoneassociates.org
Visit our pharma industry / biotech industry section for the latest news on this subject.
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/81519.php>
APA
http://www.medicalnewstoday.com/releases/81519.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



